Merci d'essayer une autre recherche
Le Fonds a pour objectif d’investissement la protection des fonds propres et l’appréciation du capital sur le long terme par l’investissement dans un portefeuille mondialement diversifié de sociétés de soins de santé. Le Fonds investira à tout moment au moins les deux tiers de son actif total (à l’exclusion du numéraire) dans des entreprises liées aux soins de santé dans le monde entier. Sous réserve des restrictions d’investissement décrites dans l’Annexe II du Prospectus, les investissements porteront sur des titres négociables, y compris, mais sans que la liste soit exhaustive, des actions, des bons de souscription d’actions et d’autres types de valeurs mobilières telles qu’actions de préférence pouvant être cotées sur un Marché réglementé ou non cotées et émises par des sociétés, ainsi que des certificats représentatifs d’actions mondiales, américaines et européennes. Le Fonds ne peut pas investir plus de 10 % de sa valeur liquidative dans des titres non cotés.
Nom | Titre | Depuis | Jusqu’à |
---|---|---|---|
James Douglas | - | 2015 | Maintenant |
Biographie | James joined Polar Capital in September 2015 and is a Fund Manager for the Healthcare team. He was appointed Co-Fund Manager for the Polar Capital Global Healthcare Trust in May 2017.Prior to joining Polar Capital, James worked in equity sales specialising in global healthcare at Morgan Stanley, RBS and HSBC. James also has equity research experience garnered from his time at UBS, where he worked as an analyst in the European pharmaceutical and biotechnology team. Before moving across to the financial sector, he worked as a consultant for EvaluatePharma. James received a PhD and first class honours degree in Medicinal Chemistry from Newcastle University. Further to this, James also holds an ACCA diploma in financial management. | ||
Gareth Powell | Portfolio Manager | 2007 | Maintenant |
Biographie | Gareth Powell joined Polar Capital in 2007 to establish the healthcare investment team. He is joint manager of the Healthcare Opportunities Fund. He joined Framlington in 1999, later becoming a portfolio manager on the Framlington Health Fund. In 2002, Gareth helped launch the Framlington Biotech Fund, which he managed until his departure. Gareth studied biochemistry at Oxford, during which time he worked at Yamanouchi, a leading Japanese pharmaceutical company (later to become Astellas), as well as various academic laboratories including the Sir William Dunn School of Pathology, the Wolfson Institute for Biomedical Research and Oxford Business School. He is a CFA charterholder. | ||
Daniel Mahony | Portfolio Manager | 2007 | 2019 |
Biographie | Daniel Mahony Ph.D. joined Polar Capital to establish the healthcare investment team in 2007. He is joint manager of the Healthcare Opportunities Fund and lead manager of the Healthcare Blue Chip Fund. Prior to joining Polar Capital, he was head of the European healthcare research team at Morgan Stanley, covering the European biotechnology, medical technology and healthcare services sectors. He also previously worked in New York for ING Barings Furman Selz following the US biotechnology sector. Before working in the investment field, Daniel worked as a research scientist for seven years with the majority of his time at Schering Plough Corporation in California. Daniel received his PhD from Cambridge University in 1995 and a first class honours degree in biochemistry from Oxford University in 1991. |
Voulez-vous vraiment bloquer %USER_NAME% ?
Si vous continuez, vous et %USER_NAME% ne verrez plus vos publications Investing.com mutuelles.
%USER_NAME% a bien été ajouté à votre Liste d’utilisateurs bloqués
Vous venez de débloquer cette personne et devrez attendre 48 heures avant de la bloquer de nouveau.
Je souhaite signaler ce commentaire comme:
Merci
Le commentaire signalé sera révisé par nos modérateurs